Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: A multi-institute study

Breast Cancer Research and Treatment

Volumn 141, Issue 2, 2013, Pages 269-275

  Kadoya, Takayuki ^a   Aogi, Kenjiro ^b   Kiyoto, Sachiko ^b   Masumoto, Norio ^a   Sugawara, Yoshifumi ^b   Okada, Morihito ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Breast cancer; Estrogen receptor; maxSUV; PET CT; Prognosis; Recurrence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAXIMUM STANDARDIZED UPTAKE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOLOGICAL PARAMETERS; RECURRENCE FREE SURVIVAL; TUMOR INVASION;

AGED; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84885319906     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2687-7     Document Type: Article

References (19)

1. Koolen BB, Vrancken Peeters MJ, Aukema TS et al (2012) 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat 131:117-126
2. Riegger C, Herrmann J, Nagarajah J et al (2012) Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging 39:852-863
3. Ohsumi S, Inoue T, Kiyoto S, Hara F et al (2011) Detection of isolated ipsilateral regional lymph node recurrences by F18-fluorodeoxyglucose positron emission tomography-CT in follow-up of postoperative breast cancer patients. Breast Cancer Res Treat 130:267-272
4. Kurata A, Murata Y, Kubota K et al (2009) Multiple (18)F-FDG, PET-CT for postoperative monitoring of breast cancer patients. Acta Radiol 50:979-983
5. Dimitrakopoulou-Strauss A, Strauss LG et al (2004) Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 45:1480-1487
6. Tsutani Y, Takuwa T, Miyata Y et al (2013) Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma. Ann Oncol 24:1005-1010
7. Tsutani Y, Miyata Y, Misumi K et al (2011) Difference in prognostic significance of maximum standardized uptake value on [18F]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol 41:890-896
8. Morris PG, Ulaner GA, Eaton A et al (2012) Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer 118:5454-5462
9. Straver ME, Aukema TS, Olmos RA et al (2010) Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging 37:1069-1076
10. Wang Y, Zhang C, Liu J et al (2012) Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat 131:357-369
11. The Japanese Breast Cancer Society (2012) General rules for clinical and pathological recording of breast cancer, 17th edn. Kanehara, Tokyo
12. Westerterp M, Pruim J, Oyen W et al (2007) Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 34:392-404
13. Wang Y, Yin Q, Yu Q et al (2011) A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat 130:489-498
14. Munzone E, Botteri E, Sandri MT et al (2012) Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer 12:340-346
15. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736-1747
16. Safar V, Dupuis J, Itti E et al (2012) Interim [18F] fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 30:184-190
17. Goldhirsch A, Coates AS, Gelber RD et al (2006) First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 12:1772-1776
18. Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 8:1319-1329
19. Ohara M, Shigematsu H, Tsutani Y et al (2013) Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer - usefulness for malignant grade of triple-negative breast cancer. Breast. doi: S0960-9776(13)00106-9